Akorn Faces Hurdles In Returning To Path Of Profitable Growth

A new management team at Akorn is making progress on moving on from Fresenius Kabi’s ill-fated takeover bid; but putting manufacturing problems behind the US injectables and ophthalmics specialist is proving difficult.

Trees
Akorn is far from finding its way out of the woods on FDA manufacturing compliance issues • Source: Shutterstock

“Akorn has recently faced multiple obstacles in the form of increased competition to many of our key products, supply issues, and regulatory and legal challenges,” the US firm’s recently appointed president and chief executive officer, Doug Boothe, acknowledged on his first results call for the ophthalmics and injectables specialist.

Recognizing that there was “a lot of work to be done to return our company to the path of profitable...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business